We'll be joining Intel in their booth #2661 to share insights on NGS-based genetic testing across a range of cancer, hereditary, and rare diseases and you're welcome to stop by to learn more. We would also like to invite you to join the HIMSS17 Lunch & Learn: Enabling Precision Medicine Through NGS-based Screening and Diagnostic Testing
Monday, February 20, 2017, 11:15 am – 12:15 pm, Room 202A
Speakers
Ramon Felciano, CTO and Vice President,
Technology and Global Strategy Global Manager, Clinical Testing Solutions, QIAGEN Bioinformatics
And
Kristina Kermanshahche, Global Director Life Sciences, Intel
Our topics include NGS-based genetic testing across a range of cancer, hereditary, and rare diseases.
Learn how a leading academic hospital used a robust informatics platform to accelerate the deployment of validated precision medicine capabilities from sample to insight.
We (QIAGEN) provide an instrument-, platform-, assay- and pipeline-agnostic solution, that enables health care providers to scale sequencing, analysis, interpretation and reporting of screening, diagnostic and monitoring test offerings, fully integrated with hospital information systems.
Join the discussion on the importance of cost-effective and automated approaches for scaling an organizational capacity for analysis, classification and clinical reporting of relevant variants for delivery to physician providers.
Register online now to ensure a seat
If this is the first you've heard about HIMSS17 - which is the Health IT Conference 2017 - you can find more information on their website http://www.himssconference.org
In the coming months, we have a number of webinars prepared for you. You can meet our experts and get introductions, tips and tricks to our solutions for use in hereditary diseases and cancer research.
You can find more details below. And you can of course sign up for the webinars right now!
October 15th, 2015 at 10am PST
Unravelling the complexity of non-syndromic inherited diseases - A case for whole exome sequencing and NGS interpretation
Join Dr. Hywel Williams, head of the UCL Center for Translational Omics, also known as GOSgene in this educational webinar that illustrates the power of whole-exome sequencing (WES) and analysis for the identification of known and novel variants associated with complex non syndromic inherited diseases. In this webinar Dr. Williams will provide an overview of his study in the contact of a phenotype that has not been previously described in the literature, and makes the case for broader adoption of WES and NGS interpretation with Ingenuity Variant Analysis to increase the rate of successfully solved cases, and improved patient outcomes.
Register
September 22nd at 10am PST
Solve More Diagnostic Odyssey Cases - The Case for a Comprehensive and Accurate Knowledge Base
This webinar focuses on Ingenuity Variant Analysis – the accurate, manually-curated, comprehensive Knowledge Base 15+ years in the making, and the ability to rapidly isolate causal variants and relationships while reducing the follow-up effort invested in pursuing benign or false leads.
Register
September 15th at 10am PST and September 17th at 10am CET
A rapid and highly accurate end-to-end NGS analysis solution for detection of novel inherited disease mutations
This webinar highlights QIAGEN’s new, highly accurate, and integrated end-to-end NGS analysis solution for the discovery of novel, and clinically relevant, rare and inherited disease causing variants, from various sample types in just one step. QIAGEN’s Dr. Anika Joecker will demonstrate the easy to use end-to-end hereditary disease workflows in Biomedical Genomics Workbench and Ingenuity Variant Analysis, as well as the Allele Frequency Community – an extensive, high-quality, ethnically diverse collection of human allele data for use as a reference set. Special attention will be devoted to demonstrating the impact of accuracy and time-savings associated with reducing the number of false positives when searching for disease causing mutations in NGS data.
Register for September 15th NA
Register for September 17th CET
The BioConference Live virtual event on cancer research and oncology takes place September 30 - October 1, 2015. The event includes Mini-Symposiums and presentations from experts on different aspects of cancer research.
We're hosting two webinars at this virtual conference:
Role of microRNA-mRNA interactions in Endometrioid Endometrial Carcinoma, a “Sample to Insight” biological exploration.
Presented by Jean-Noel Billaud Ph.D., Principal Scientist, QIAGEN Bioinformatics
October 1st at 9-10 AM (PST)
RNA-editing in melanoma – Case for a sensitive analysis and interpretation platform for the resolution of a diverse molecular process and likely pathogenic variants
Presented by Dr. Anika Joecker, Global Product Manager, QIAGEN Bioinformatics
Additional information about the speakers
Registration
Recordings of the presentations will be available after the conference.
Oct 6th - Oct 10th, 2015
ASHG 2015 will be held in Baltimore, Maryland from Tuesday, October 6 through Saturday, October 10, 2015.
It's the 65th ASHG and the meeting provides a forum for the presentation and discussion of cutting-edge science in all areas of human genetics: at invited platform and poster sessions, on the trade show floor, and at interactive workshops and events.
QIAGEN Bioinformatics team will be in Booth #1622 ready to show you how our Sample to Insights solutions can help you in your research. We will be demonstrating Ingenuity® Variant Analysis™, Biomedical Genomics Workbench, HGMD, and Inova Genomes — and we’d be happy to answer your questions.
We also invite you to stop by the QIAGEN booth #1621 across the aisle to learn about sample to insight solutions for exosomes, FFPE, circulating nucleic acids and single cells.
We have a number of QIAGEN Bioinformatics executives participating in educational sessions.
10-min presentation:
Workshop:
This event will be held in room Loch Raven, 2nd floor, Sheraton Inner Harbor Hotel.
Poster sessions:
For more than six decades, the American Society of Human Genetics Annual Meeting has offered the latest news and views about all areas of human genetics. This year, in its 65th iteration, ASHG promises to uphold that tradition: it will take place from October 6-10 at the Baltimore Convention Center, where more than 6,500 attendees from around the globe will learn about and discuss cutting-edge research in the field. For QIAGEN Bioinformatics, the conference offers a chance to focus on hereditary diseases, including cancer, and our various platforms, tools, and partnerships that allow researchers to further their work, including hereditary and rare disease analysis and interpretation in one solution with Biomedical Genomics Workbench and Variant Analysis with HGMD®, Inova Genomes, QIAGEN® Clinical Insight (hereditary cancer application) and collaborative enterprises like the Allele Frequency Community.
Listed as one of the best conferences to attend by a GenomeWeb survey, ASHG is well known for its broad scope and insightful content. The 2015 agenda offers a number of intriguing sessions — from symposia and workshops to keynotes and poster sessions — with topics including the genetics of disease, science communication, and policy updates, among many others. In addition to its abundant opportunities for scientists to network and learn through interactive sessions, ASHG features a large exhibition space, where more than 3,000 posters will be on display and more than 200 companies will provide updates on their products and services.
Several sessions stand out on the ASHG agenda this year. Kicking off the meeting, ASHG President Neil Risch will address how, through research and clinical practice, genetics is poised to make a significant impact on society and technology. Immediately following that session, Risch will host a symposium about the progress of genomics and electronic health records with four thought leaders in this space. In addition, several sessions will drill down into the genetics of disease, which is helping to move the needle on more effective medical treatment.
We’re particularly pleased to see such a focus on NGS analysis and interpretation — several of the scientific sessions will report on new methods as well as case studies of how high-quality analysis and interpretation made a difference. Many of the sessions also touch on the importance of analyzing more diverse populations. As co-founders of the Allele Frequency Community, we heartily support efforts to expand our public genetic databases to reflect variation seen in even very small ethnic populations.
For more information on ASHG, click here.
